Regeneron Pharmaceuticals Inc (REGN) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
Regeneron Pharmaceuticals Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Regeneron Pharmaceuticals Inc 's ROA in the third quarter of 2026? Regeneron Pharmaceuticals Inc achieved a return on average assets (ROA) of 11.5 % in its third quarter of 2026, which is below Regeneron Pharmaceuticals Inc 's average return on assets, which stands at 15.52%.
ROA has improved compared to 10.6% in the second quarter of 2026, due to net income growth.
However, within the Healthcare sector 83 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 555, from total ROA ranking in the second quarter of 2026 at 601.
Dupixent s Expanding Horizons: A Game-Changer in Combating Respiratory Diseases and Allergic Conditions Beijing, China - The healthcare landscape continues to be redefined as Dupixent (dupilumab) sets unprecedented milestones across the globe. Recently, the Chinese National Medical Products Administration granted approval for Dupixent as the first-ever biologic medicine for patients suffering from Chronic Obstructive Pulmonary Disease (COPD). This pivotal approval follows closely on the heels of its authorization by the European Union for adults with COPD characterized by raised blood eosinophils. The decision is profoundly underpinned by the robust outcomes from two landmark Phase 3 trials, marking a significant breakthrough in COPD management. Landmark Phase 3 Trials: A Turning Point for COPD PatientsThe comprehensive Phase 3 trials delivered compelling evidence that Dupixent notably reduced exacerbations, improved lung function, and enhanced health-related quality of life for COPD patients. These results are not merely statistical triumphs but substantial strides toward elevating the standard of care for millions affected by this debilitating respiratory condition.
In a remarkable advancement for the treatment of chronic respiratory conditions and advanced cancers, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as the first and only treatment option for adolescents aged 12 years and older suffering from chronic rhinosinusitis with nasal polyps (CRSwNP) following a rigorous priority review process. This landmark decision marks a significant milestone in addressing the pressing needs of a demographic often overlooked in specialty medication access, underscoring the necessity of providing effective therapies for younger patients grappling with inadequately controlled CRSwNP.The availability of Dupixent for adolescents fills a critical gap in treatment options. CRSwNP is a persistent and debilitating condition characterized by chronic inflammation that leads to the growth of nasal polyps, causing substantial respiratory distress and negatively impacting overall quality of life. With Dupixent s dual mechanism of action targeting interleukin-4 and interleukin-13 pathways, this therapy effectively reduces inflammation, thus alleviating the symptoms associated with CRSwNP. The approval presents an essential addition to the therapeutic arsenal for young patients confronting the challenges of this chronic disease.
Comment on REGN's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA deteriorated to 8.86 %, despite annual net income growth of 2.09 % to $4,504.90 million, from $4,412.60 million a year ago, as REGN's assets increase to $50,819.30 million, by 2.09 %.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
